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IMRTBackground and purpose: In order to increase local tumour control by radiotherapy without increasing
toxicity, it appears promising to harness functional imaging (FI) to guide dose to sub-volumes of the tar-
get with a high tumour load and perhaps de-escalate dose to low risk volumes, in order to maximise the
efﬁciency of the deposited radiation dose.
Methods and materials: A number of problems have to be solved to make focal dose escalation (FDE) efﬁ-
cient and safe: (1) how to combine ambiguous information from multiple imaging modalities; (2) how to
take into account uncertainties of FI based tissue classiﬁcation; (3) how to account for geometric uncer-
tainties in treatment delivery; (4) how to add complementary FI modalities to an existing scheme. A gen-
eric optimisation concept addresses these points and is explicitly designed for clinical efﬁcacy and for
lowering the implementation threshold to FI-guided FDE. It combines classic tumour control probability
modelling with a multi-variate logistic regression model of FI accuracy and an uncomplicated robust
optimisation method.
Results: Its key elements are (1) that dose is deposited optimally when it achieves equivalent expected
effect everywhere in the target volume and (2) that one needs to cap the certainty about the absence
of tumour anywhere in the target region. For illustration, an example of a PET/MR-guided FDE in prostate
cancer is given.
Conclusions: FDE can be safeguarded against FI uncertainties, at the price of a limit on the sensible dose
escalation.
 2014 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 111 (2014) 354–359
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/3.0/).Functional imaging modalities (FI), e.g. various magnetic reso-
nance imaging techniques (MRI) or positron emission tomography
(PET) with various tracers, are increasingly being linked to tumour
physiology or shown to have predictive or prognostic value [1].
Prevalent local failure in some tumour entities forms the rationale
for a focal escalation of radiation dose (FDE) which is under inves-
tigation in pioneering clinical trials [2–5]. When it comes to quan-
titative use of FI, image interpretation and – quality quickly
become an issue. Reported values of sensitivity and speciﬁcity of
the most promising FI are usually in the range of 0.7–0.8, despite
a multitude of technical challenges that have been mastered to
establish reproducibility [6–8]. Apart from the large inﬂuence of
inter-patient heterogeneity, volumetric pathologic ground truth
for quantitative validation is cumbersome to obtain, limited in
sample size and fraught with uncertainties of its own [9]. The com-
bination of multiple FIs can increase sensitivity and speciﬁcity toup to 0.9 [10,11], but leaves the question how multiple FI can be
harnessed for FDE.
FI-guided FDE can be achieved via a binary prescription dose
map [12]. For example, Korporaal et al. [13] derived a logistic
regression model from expert image classiﬁcation of dynamic con-
trast enhanced (DCE) computed tomography and established
tumour classiﬁcation in prostate by thresholding. Langer et al.
[14] and Groenendaal et al. [9,10] combined multiple MRI modal-
ities via a logistic regression model and obtained binary tumour
maps for prostate cancer via thresholding. Both models were
derived from expert readings, and only the latter was validated
against pathology. In this rapidly growing ﬁeld, new FI are devel-
oped so quickly that a quantitative, volumetric pathologic valida-
tion may not commonly be available for any combination of
modalities, thus raising the question how individually validated
modalities can be combined with beneﬁt.
As an alternative to binary volumes, Oberhammer et al. [15]
interpreted the result of a support vector regression model as a
pointwise probability of tumour presence. Subsequently, the dose
prescription was directly based on this 3D probability map,
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Here, we combine the advantages of both concepts to suggest a
solution to four practical problems in FI-guided FDE: (1) how to
amalgamate the information from multiple imaging modalities;
(2) how to take into account uncertainties of FI-based tissue clas-
siﬁcation; (3) how to account for geometric uncertainties in treat-
ment delivery; (4) how to incorporate additional FI to an existing
scheme without having to establish volumetric pathologic ground
truth for every new modality in combination with the others.
The concept is exempliﬁed by a prostate case, comprising Diffu-
sion-Weighted Imaging (DWI), resulting in an Apparent Diffusion
Coefﬁcient Map (ADC), dynamic contrast enhanced (DCE) MRI,
yielding the parameter Ktrans and [18F]-Choline PET, simultaneously
acquired on a PET/MR scanner.
Methods and materials
Probability of tumour presence
Assumea set ofnproperly registeredFIswith intensities I1...nðxÞ in
N image points x is given. We choose a multivariate logistic regres-
sion model. Let the probability of ﬁnding tumour in the location x
pðxÞ ¼ 1
1þ expðc0 
Pn
i¼1ciIiðxÞÞ
: ð1Þ
The regression coefﬁcients ci; i ¼ 0 . . . n need to be determined ide-
ally from pathology, expert readings, a pattern of failure analysis, or
using alternative strategies (see example case). Notice that the
logistic regression model assumes that the FI are independent,
which needs veriﬁcation especially for some MRI methods. The det-
rimental effect of correlations can be dealt with as presented in
‘Derivation of odds from image intensity’.
For the following, it is helpful to review the alternative formu-
lation of the logistic regression function in terms of the odds Ri:
pðxÞ ¼ 1
1þQni¼1RiðIiðxÞÞ : ð2Þ
In other words, if the image intensity IðxÞ is found in point x, it is
RðIÞ times more likely to ﬁnd no tumour there than to ﬁnd any. Per-
fect certainty of tumour presence equals R ¼ 0, while certainty
about tumour absence is asymptotically approached if R !1. In
the case of volumes where p is small, a good approximation to Eq.
(2) can be found
logðpÞ ¼  log 1þ
Yn
i¼1
Ri
 !
K 
Xn
i¼1
log Ri ð3Þ
that illustrates how and with which weighting individual imaging
modalities contribute independently to the local probability of
tumour presence.Maximizing tumour control in the presence of imaging uncertainties
The most commonly used measure for success in radiotherapy
is the tumour control probability Q, i.e. treatment quality is mea-
sured in terms of a high likelihood of achieving the desired result.
We extend this concept by the classiﬁcation probability p, assum-
ing that the tumour control probability qðDðxÞÞ at dose DðxÞ in
point x is independent of its neighbours [16]. We ﬁnd
Q ¼
Y
x
1 pðxÞ½  þ pðxÞqðxÞ½ ð Þ; ð4Þ
where the ﬁrst term is the tumour control when the point is indeed
free of tumour and the second term the tumour control by the treat-
ment else. For the purposes of dose optimisation, it is beneﬁcial to
choose  logðQÞ as a cost function [17]. We ﬁnd logðQÞ ¼ 
X
x
log 1 pðxÞð1 qðxÞÞð Þ ð5Þ

X
x
pðxÞð1 qðxÞÞ ð6Þ
by a Taylor expansion of logð1 Þ  . Notice that in the context
of dose optimisation, we can restrict ourselves to the situation of
doses yielding reasonable tumour control, in other words the prob-
ability of failed cell kill 1 qðxÞ is typically in the order of 102 cm3.
It is frequently expressed as 1 q ¼ C expðaD bD2Þ with some
cell-density-dependent constant C. Thus, the tumour presence prob-
ability pðxÞ acts like a local cost function density weight, which is in
keeping with its interpretation as a probability of a systematic clas-
siﬁcation error (see discussion). With the right calibration of C, the
cost function becomes the expected number of surviving tumour
cells given the uncertainty about their presence.Accounting for systematic and random treatment uncertainties
The probability of tumour presence pðxÞ is deﬁned in the patient
coordinate system. For treatment planning, the patient coordinate
system has to be aligned with the treatment coordinate system.
Naturally, the treatment plan and therefore also the optimum dose
are deﬁned relative to the treatment coordinate system. Random
errors (with probability distribution Tðx; x0Þ) and systematic errors
(with probability distribution Sðx; x0Þ) displace the points of the
patient coordinate system relative to the treatment coordinate sys-
tem. The effect of random errors, especially in a treatment with
many fractions and a deep-seated target, is an averaging of the
dose delivered to point x, which can be dealt with at several levels
of approximation, depending on the target location. For the exam-
ple below, we choose the dose convolution approach [18,19] which
is appropriate if a random error does not affect the dose in the
treatment coordinate system.
Systematic errors lead to an uncertainty about the classiﬁcation
of a point x at a location x0 in the treatment coordinate system. For
cost functions of the type of Eq. (5), a coverage probability sðx0Þ can
be computed [20–23]:
sðx0Þ ¼
Z
Sðx; x0Þdx: ð7Þ
The cost function for the target in treatment coordinate system then
reads
F ¼  logðQÞ ¼ C
X
x0
Z
pðxÞSðx; x0Þdx
 
expðaDðx0ÞÞ; ð8Þ
where the constant C could be dropped for convenience. For sim-
plicity of the following argument, the fraction size dependence of
the linear-quadratic-formalism has also been omitted. The integral
~p ¼ R pðxÞSðx; x0Þdx is the composite classiﬁcation probability origi-
nating from FI interpretation uncertainty and systematic patient
geometry errors in dose planning. Coverage probability can be
applied to other cost functions such as equivalent uniform dose
(EUD) or DVH penalties analogously.Derivation of odds from image intensity
For clarity of argument, we start with
F ¼ C
X
x
pðxÞ expðaDðxÞÞ
¼ C
X
x
exp a DðxÞ  1
a
logðpðxÞÞ
  
: ð9Þ
The optimum dose distribution DðxÞ is required to employ the
deposited energy with maximum efﬁciency for cell kill. This
amounts to the requirement that the derivative with respect to D
of all terms of the sum is equal in all points x, i.e. an additional dose
Table 1
Parameters for the logistic regression model of the probability of local tumour
presence. Parameters in bold obtain from the other parameters that are either derived
from [10] or ﬁxed by convention.
FI-calibration Rmax Ilow Imed c pmin
ADC-1 3 1:47  103 1:18  103 3:8  103 0.25
ADC-2 3.2 1:47  103 1:18  103 4:0  103 0.24
trans
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We introduce the nominal prescription dose Dpresc to certain (p ¼ 1)
tumour locations and ﬁnd
aC expðaDprescÞ ¼ aC exp a DðxÞ  1a logðpðxÞÞ
  
: ð10Þ
Thus,
DðxÞ ¼ Dpresc þ 1a logðpðxÞÞÞ ð11Þ
KDpresc  1a
Xn
i¼1
logRiðxÞ: ð12Þ
This inequality is illustrative if some or all FI indicate that a point is
likely tumour-free, i.e. at least some of the odds Ri are large. Each FI
allows a dose reduction to a likely tumour-free point proportionally
to the logarithm of the odds, which amounts to relatively little. For
example, assume a FI indicates a minimum probability of tumour of
pmin ¼ 0:25, equalling R ¼ 3, or a possible dose reduction by 4 Gy if
a ¼ 0:28 Gy1. The worst-case scenario of multiple FI having high
odds in one point (all predict no tumour presence), but not being
independent, leads to the composite odds
Qn
i¼1Ri being overesti-
mated. This can be prevented by introducing a maximum Ri;max for
the individual and Rmax for the composite odds.
An estimate of pmin can be obtained from the published sensitiv-
ity s of the FI in question. In principle, 1 pmin equals the negative
predictive value. However, the latter depends on prevalence, in our
case: the fraction of the target organ occupied by tumour cells.
Since this quantity is hard to obtain and highly variable in a popu-
lation, we assume that the prevalence is 0.5, which results in
pmin 6 1 s. For typical sensitivities s ¼ 0:75 for single modalities
and s ¼ 0:9 for combined modalities, the limits of Ri;max ¼ 3 and
Rmax ¼ 9, respectively, can be obtained. From this follows that the
maximum safe dose reduction equals 8 Gy for a ¼ 0:28 Gy1 and
15 Gy for a ¼ 0:15 Gy1. Notice that by equating the minimum
tumour classiﬁcation pmin ¼ 1 s, we force the tumour classiﬁca-
tion model to be as imprecise for every individual patient as the
diagnostic model is for a population. In other words, a diagnostic
classiﬁcation model can be absolutely certain about tumour
absence, but this assessment can be wrong with probability 1 s.
The modiﬁcation we suggest makes the model only certain up to
the residual chance pmin that tumour is absent.
We now address the inclusion of a new FI into an already exist-
ing setup, ideally without having to test the combination ﬁrst,
assuming each FI is validated independently. Observe that within
the logistic regression model, the log-odds are a linear function
by deﬁnition. With the maximum odds established above, we ﬁnd:
log R ¼ log Ri;max I 6 Ilow
log Ri;max=ðImed  IlowÞðImed  IÞ I > Ilow:

ð13Þ
With the choice of Ri;max, two more parameters sufﬁce to deﬁne
the calibration from image intensities to log-odds (see Fig. 1): the
image intensity Imed, where the image is perfectly ambiguous
(R ¼ 1), and the intensity Ilow where the signal suggests absence
of tumour.1 Notice, that the dose prescription depends more sensi-
tively on Rmax than on the other two parameters. Expressed in the
parameters of Eq. (1), we ﬁnd for the individual contribution to
c0; c0;i ¼  logRi;maxImed=ðImed  IlowÞ and ci ¼ logRmax=ðImed  IlowÞ.
Example
The example is an 80 y.o. prostate cancer patient who was
examined prior to radiotherapy with combined PET/MR (Biograph1 The formula is given for a PET-like signal: more intensity means higher presence
of the quality of interest. The I-axis reverses for example for MRI-ADC.mMR, Siemens Healthcare, Erlangen, Germany) using [18F]-Choline
as a PET tracer. After a fast series of diagnostic MR scans, DCE- as
well as DWI/ADC-MR sequences were applied according to [9] to
obtain maps of Ktrans and ADC. The Ktrans map was normalised
[10]. This was part of an image validation study, within which each
patient received a clinically indicated PET/CT. PET/MR images were
obtained directly after PET/CT imaging with no additional tracer
injection. PET/MR acquisition started 58 min after the injection of
a total choline dose of 591 MBq. For treatment planning purposes,
combined PET/MR data were rigidly matched to CT.
For image calibration, i.e. determination of regression factors ci
for ADC and Ktrans, two approaches were employed. Both rely on the
data in [10], where the population averaged intensities for ADC and
Ktrans are given for suggestive and non-suggestive volumes. We
choose Ilow to be equal to the mean intensity of the non-suggestive
volumes, and Imed to be the average between the suggestive and the
non-suggestive. For method 1, we then ﬁx the maximum individ-
ual odds Ri;max ¼ 3, and compute ci. For method 2, we use the pub-
lished regression factor ci and compute the corresponding
maximum odds. All values are shown in Table 1. In addition to
these MR images, Choline-PET was added following method 1.
Each FI can produce a classiﬁcation probability separately, or in
combination with others. To see the effect of adding modalities,
Fig. 2 shows histograms of the voxelwise classiﬁcation probability
for the example patient. A more trusted single modality covers a
wider range of classiﬁcation probabilities. The effect of combining
modalities is typically that the range of probabilities is stretched
and the histogram becomes more bi-modal (the classiﬁcation
becomes more deﬁnitive). The histogram would only become less
bi-modal if two modalities contradict each other. An unspeciﬁc
modality would result in a horizontal shift. Of note, the two meth-
ods become more similar when both MRI-FI are used for classiﬁca-
tion. In the example, Ktrans alone does not discriminate strongly
between suggestive and non-suggestive points, while ADC alone
is quite effective. The low speciﬁcity of Choline-PET can be read
from the broad and not very peaked distribution.
Tumour classiﬁcation probability maps are shown in Fig. 3:
MRI-only by method 1 in Fig. 3a, MRI-only by method 2 in
Fig. 3b, MRI + PET by method 1 in Fig. 3c, and MRI + PET convolved
with the coverage probability kernel in Fig. 3d. The coverage prob-
ability kernel had a Gaussian shape with a width of 4r and
r ¼ 3 mm, 5 mm, and 4 mm in lateral, anterior-posterior and cra-
nio-caudal directions, respectively.
Dose optimisation was performed with a number of physical
and EUD-based dose constraints that were determined by creating
a homogeneous 78 Gy treatment to the entire PTV, for delivery as a
conventional 15 MV rotational IMRT (a = 0.25 Gy1). With the
same constraints, plans were generated for a nominal prescription
dose D to the tumour foci of 95 Gy, equivalent to the FLAME trial
[24]. The cost function Eq. (5) has no built-in limit for FDE so that
an additional limit has to be formulated. For sufﬁcient freedom to
distribute the excess dose of the FDE, we limit the total deposited
energy to the same amount as delivered for the homogeneousK -1 3 1.19 1.62 2.55 0.25
Ktrans-2 2.3 1.19 1.62 1.9 0.30
PET-1 3 1.0 1.5 2.2 0.25
Ilow Imed Imax0
Image Intensity
0
log Rmax
lo
g 
od
ds
Fig. 1. Schematic illustration of the calibration of log-odds from image intensities.
Rmax is the maximum odds for the absence of tumour where the image intensity is at
Ilow , e.g. SUV = 1 for a PET image. Imed is the image intensity that corresponds to a
50:50 chance of ﬁnding tumour, i.e. an odds of 1.
Fig. 2. Histograms of tumour classiﬁcation probabilities for the semi-heuristic (top)
and model-ﬁt (bottom) method for single image modalities and their combinations.
M. Alber, D. Thorwarth / Radiotherapy and Oncology 111 (2014) 354–359 35778 Gy treatment. Fig. 3e and f show the treatment plans for the
semi-heuristic MRI + PET and the model-ﬁt MRI-only prescriptions.Discussion
The presented method translates uncertainties in FI tumour
classiﬁcation and treatment delivery into a prescription for FDE.
It embodies the economic rationale that dose should be equallyeffective everywhere. The resulting dose prescription function
resembles ‘‘dose painting by numbers’’ (DPBN) [25,26], but its
rationale is entirely different. Here, we want to deliver a uniform
dose to all tumour foci, but the uncertainty about tumour presence
results in a lower expected beneﬁt of dose in potentially tumour-
free points. It is illustrative to think of it as image-guided de-esca-
lation in low risk volumes. If the volume was homogeneously clas-
siﬁed as tumour, the ideal dose would be homogeneous. In
contrast, DPBN directs dose according to its efﬁcacy in a biologi-
cally heterogeneous tumour; therefore, the ideal dose is not uni-
form. By virtue of the assumption of equal limiting beneﬁt in Eq.
(10), both concepts could be combined by making the constants
a; C dependent on x [27]. However, this requires that an (possibly
additional) imaging modality correlates with a tumour quality,
such as cell sensitivity, and not simply tumour presence, as in this
framework.
We employ a continuous classiﬁcation function fromwhich vol-
umes like a ‘‘low risk CTV’’, ‘‘high risk CTV’’ and ‘‘GTV’’ could be
obtained by thresholding [10,13]. By using a continuous risk scale
for dose prescription, these additional threshold parameters can be
omitted. The logistic classiﬁcation function is linear both in each
single FI intensity and between multiple FIs. The latter allows us
to expand existing imaging schemes with additional modalities
easily. While a precise calibration of the classiﬁcation function
appears indispensable from a diagnostic accuracy point of view,
it is the logarithm of the function that enters the dose prescription.
Errors in the classiﬁcation probability of suggestive volumes do not
matter much (DD ¼ 1=a logðp ¼ 1 Þ  =a). However, errors
in the classiﬁcation probability of non-suggestive volumes are
ampliﬁed. To safeguard against erroneous dose de-escalation, a
minimum probability of tumour presence, or maximum odds
Rmax, were introduced. Because of this modiﬁcation, the model
parameters can also be obtained from a practical heuristic. This
is particularly important if some FI modalities have been tested
individually, but not in combination. The quality of the test should
be reﬂected in the choice of Ri;max. We consider
pmin ¼ 0:25; Ri;max ¼ 3 for individual and pmin ¼ 0:1; Rmax ¼ 9 for
combined modalities generally cautiously optimistic. With these
limits, the dose spread between tumour foci and low-risk volumes
turns out to be in the range of 10–15 Gy. Larger spreads could only
be justiﬁed if the imaging sensitivity for some combination of
modalities exceeds 90%, or other effects like hypoxia contributed
to a lower radiation sensitivity in larger foci. Especially in the con-
text of the example, FI may indicate a higher Gleason score and
thereby justify a greater spread.
The example dose plans were chosen to illustrate the effect of
complementary image information on the dose prescription. For
the MRI-only prescription, the tumour classiﬁcation probability
anywhere in the volume was slightly higher, and this translates
into an approximately 1–3 Gy greater dose to the non-suggestive
volume. The tumour focus appears better deﬁned in the MRI + PET
case, which results in a larger boost volume. An additional FI can
increase the certainty about tumour absence and therefore justify
a greater dose spread. Multiple FIs also dilute the effect of errors
in a single image (see Eq. (11)). The relatively shallow prescription
dose gradients pose no problem for modern IMRT delivery. It must
be noted that functional imaging is still subject to a large operator
variability and further efforts are necessary to establish inter-insti-
tuional consistency of data derived from functional imaging.
Alternative classiﬁcation functions have been suggested, e.g.
support vector machines [15,28,29], pattern recognition [30], and
statistical methods [31–33]. Still, none of the more sophisticated
methods offers a signiﬁcantly better accuracy, reﬂecting that func-
tional imaging is often a gaze into a rather dull crystal ball, clouded
by inter-patient heterogeneity, image resolution and contrast, reg-
istration errors and non-speciﬁcity. We consider it crucial that any
Fig. 3. Top row: raw tumour classiﬁcation probability p for MRI-only obtained from the semi-heuristic method 1 and a model parameter ﬁt (method 2) (a, b). Middle row:
raw tumour classiﬁcation probability p for MRI + PET obtained from the semi-heuristic method 1 (c) and the corresponding ~p enhanced by coverage probability (d). Bottom
row: dose distributions for the prescription map of (MRI + PET) x coverage probability (e) and for MRI x coverage probability (e). The high probability in the centre of the
prostate is a MR-artefact caused by the urethra, which is dampened by the addition of PET. It was not removed for illustration purposes, to demonstrate the classiﬁcation
probability dependent dose levels.
358 Dose painting and uncertaintiesalternative model also be safeguarded with a lower limit on the
probability of tumour presence.
The standard approach to deal with treatment-related uncer-
tainties is the expansion of the target volume by a margin. Techni-
cally, this could be approximated by the convolution of the
classiﬁcation map with a box function on an ellipsoid Sboxðx; x0Þ.
While this will expand the suggestive volume in the classiﬁcation
map, it will not change the structure of Eq. (8). As an alternative,
we suggest to employ a 3D-Gaussian (or similar) error distribution
that incorporates the coverage probability distributions of system-
atic treatment errors, which yields a more focussed and speciﬁc
dose prescription map. It is also a template for dealing with image
registration uncertainties between the FI modalities and the plan-
ning CT image. We suggest that each modality be blurred with the
relevant systematic uncertainty distribution before they are
blended together by the logistic regression model. This also leads
to some next-neighbour correlations that improve the model accu-
racy, as suggested by Groenendaal et al. [10]. Intriguingly, coverage
probability can be understood as the classiﬁcation uncertainty of a
point in the treatment room as being occupied by tumour, caused
by systematic patient geometry changes. The concept of ~p pro-
posed here expands this by the equally systematic uncertainty of
target volume identiﬁcation. It yields the most efﬁcient dose distri-
bution on average in a patient population, where the average runs
over the unknown systematic errors in image classiﬁcation.
Although the approach guarantees that best use is made of the
total deposited energy in a population, some patients will receivea worse-than-average treatment, whose risk can only be controlled
by realistic expectations about the power of functional imaging.Conclusions
Functional image guided dose escalation can be safeguarded
against functional imaging uncertainties, at the price of a limit
on the sensible dose escalation.Conﬂicts of interest statement
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